Cingulate (NASDAQ:CING – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AMN Healthcare Services (AMN – Research Report), Cingulate Inc (CING – Research Report ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical ...

The purpose of this study is to carry out a comprehensive analysis of changes in future runoff and flood for the upper Huai River basin by combining future climate scenarios, hydrological model, and ...